Key Takeaways
- • JW Asset Management sold 90,533 shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) between May 26–28, 2026, generating approximately $6.64 million at a weighted average price of $73.31 per share.
- • The transaction reduced JW Asset Management's indirect holdings by 3.04%, bringing total indirect ownership from approximately 2.98 million shares to 2.89 million shares.
- • The sale size of 90,533 shares exceeded JW Asset Management's historical average transaction size of approximately 25,263 shares, signaling a more substantial reduction in position.
- • The hedge fund maintained substantial exposure to Establishment Labs following the transaction, retaining nearly 2.9 million shares despite the divestment.
Summary
JW Asset Management, LLC executed a multi-day equity sale of Establishment Labs Holdings Inc., a medical device manufacturer specializing in breast implant systems, during the final week of May 2026. The hedge fund sold 90,533 shares across open-market transactions from May 26 through May 28, 2026, according to SEC Form 4 filings, generating total proceeds of approximately $6.64 million at a weighted average price of $73.31 per share.
The transaction represented a meaningful but incremental reduction in JW Asset Management's stake in the NASDAQ-listed company. The sale reduced the hedge fund's indirect holdings by 3.04 percentage points, decreasing total indirect ownership from approximately 2.98 million shares to 2.89 million shares post-transaction. Despite the divestment, JW Asset Management retained substantial exposure to Establishment Labs, maintaining nearly 2.9 million shares following the sale.
The 90,533-share sale exceeded JW Asset Management's typical transaction size, which has historically averaged approximately 25,263 shares per transaction. This larger trade size reflects either a strategic rebalancing of the position or a change in the hedge fund's conviction regarding the medical device company's near-term prospects. The transaction occurred while Establishment Labs has been expanding its market presence, having surpassed five million Motiva devices in the market globally and reporting results from its 2025 financial year.
The transaction represented a meaningful but incremental reduction in JW Asset Management's stake in the NASDAQ-listed company. The sale reduced the hedge fund's indirect holdings by 3.04 percentage points, decreasing total indirect ownership from approximately 2.98 million shares to 2.89 million shares post-transaction. Despite the divestment, JW Asset Management retained substantial exposure to Establishment Labs, maintaining nearly 2.9 million shares following the sale.
The 90,533-share sale exceeded JW Asset Management's typical transaction size, which has historically averaged approximately 25,263 shares per transaction. This larger trade size reflects either a strategic rebalancing of the position or a change in the hedge fund's conviction regarding the medical device company's near-term prospects. The transaction occurred while Establishment Labs has been expanding its market presence, having surpassed five million Motiva devices in the market globally and reporting results from its 2025 financial year.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.